Angiogenesis (clinical trials).
Therapeutic angiogenesis may play a role in the treatment of patients with vascular disease who have no other treatment option (those who are not candidates for bypass surgery or angioplasty). The first published clinical trial results appeared in 1998 and additional trials have since been completed or are ongoing. Results of several of these trials are reviewed. Studies of angiogenesis with basic fibroblast growth factor and human vascular endothelial growth factor suggest that these growth factors can induce functionally significant angiogenesis. Evolving delivery modalities and strategies are also highlighted.
Laham
R
R
Angiogenesis Research Center and BIDMC/Harvard Medical School, Boston, MA 02215, USA. rlaham@bidmc.havard.edu
D043925:Angiogenesis Inducing Agents / Q000627:therapeutic use*; D003097:Collateral Circulation / Q000502:physiology; D003327:Coronary Disease / Q000188:drug therapy*; D016228:Endothelial Growth Factors / Q000502:physiology; D006801:Humans; D008222:Lymphokines / Q000502:physiology; D018919:Neovascularization, Physiologic; D016032:Randomized Controlled Trials as Topic; D042461:Vascular Endothelial Growth Factor A; D042442:Vascular Endothelial Growth Factors
D043925:Angiogenesis Inducing Agents; D016228:Endothelial Growth Factors; D008222:Lymphokines; D042461:Vascular Endothelial Growth Factor A; D042442:Vascular Endothelial Growth Factors; C085978:fibroblast stimulating factor-1